NO20091428L - Forbindelser og metoder for 18F-merkede midler - Google Patents

Forbindelser og metoder for 18F-merkede midler

Info

Publication number
NO20091428L
NO20091428L NO20091428A NO20091428A NO20091428L NO 20091428 L NO20091428 L NO 20091428L NO 20091428 A NO20091428 A NO 20091428A NO 20091428 A NO20091428 A NO 20091428A NO 20091428 L NO20091428 L NO 20091428L
Authority
NO
Norway
Prior art keywords
compounds
methods
labeled agents
labeled
agents
Prior art date
Application number
NO20091428A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Brumby
Lutz Lehmann
Ananth Srinivasan
Detlev Suelzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20091428L publication Critical patent/NO20091428L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
NO20091428A 2006-09-08 2009-04-07 Forbindelser og metoder for 18F-merkede midler NO20091428L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules
PCT/EP2007/008042 WO2008028688A2 (en) 2006-09-08 2007-09-07 Compounds and methods for 18f labeled agents

Publications (1)

Publication Number Publication Date
NO20091428L true NO20091428L (no) 2009-06-03

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091428A NO20091428L (no) 2006-09-08 2009-04-07 Forbindelser og metoder for 18F-merkede midler

Country Status (20)

Country Link
US (1) US8557776B2 (cg-RX-API-DMAC7.html)
EP (5) EP3056509A1 (cg-RX-API-DMAC7.html)
JP (2) JP5603074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090058553A (cg-RX-API-DMAC7.html)
AR (1) AR062726A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007294124A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716554A2 (cg-RX-API-DMAC7.html)
CA (2) CA2662449A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002620A1 (cg-RX-API-DMAC7.html)
CO (1) CO6150196A2 (cg-RX-API-DMAC7.html)
CR (1) CR10654A (cg-RX-API-DMAC7.html)
IL (4) IL197363A0 (cg-RX-API-DMAC7.html)
MA (1) MA30780B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009002492A (cg-RX-API-DMAC7.html)
NO (1) NO20091428L (cg-RX-API-DMAC7.html)
PE (1) PE20080850A1 (cg-RX-API-DMAC7.html)
RU (1) RU2009112716A (cg-RX-API-DMAC7.html)
TN (1) TN2009000063A1 (cg-RX-API-DMAC7.html)
TW (1) TW200829277A (cg-RX-API-DMAC7.html)
WO (1) WO2008028688A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056509A1 (en) 2006-09-08 2016-08-17 Piramal Imaging SA Bombesin analogues for use in diagnosis
MX2009009291A (es) * 2007-03-01 2009-12-14 Bayer Schering Pharma Ag Compuestos activos biologicamente marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo.
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
AU2012267998A1 (en) * 2011-06-09 2014-01-09 Ge Healthcare Limited Distillation device and method
AU2014228233B2 (en) * 2013-03-15 2019-02-28 Cancer Targeted Technology Llc 18F-labeled PSMA-targeted pet imaging agents
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
TW202426655A (zh) 2017-07-11 2024-07-01 美商新索思股份有限公司 非天然核苷酸之導入及其方法
US11622993B2 (en) 2017-08-03 2023-04-11 Synthorx, Inc. Cytokine conjugates for the treatment of autoimmune diseases
AU2019256714A1 (en) * 2018-04-20 2020-11-12 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
KR20210123299A (ko) 2019-02-06 2021-10-13 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
KR20250164815A (ko) 2023-03-31 2025-11-25 닛산 가가쿠 가부시키가이샤 피라졸 화합물 및 유해 생물 방제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002897A1 (en) 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
HU208439B (en) * 1988-10-14 1993-10-28 Univ Tulane Process for producing pharmaceutical peptides
DE69023500D1 (de) * 1989-06-02 1995-12-14 Univ Georgetown Verfahren zum nachweis von antikörpern gegen streptokinase.
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2092599A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
WO2000076971A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
AU2002228725A1 (en) * 2000-11-30 2002-06-11 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1497317B1 (en) 2002-04-09 2006-09-06 Eli Lilly And Company Dipeptidic growth hormone secretagogues
EP1527086B1 (en) * 2002-08-09 2008-01-09 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CA2516685A1 (en) 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
EP1912634A4 (en) 2005-07-29 2010-06-09 Bayer Healthcare Llc PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
EP3056509A1 (en) 2006-09-08 2016-08-17 Piramal Imaging SA Bombesin analogues for use in diagnosis

Also Published As

Publication number Publication date
BRPI0716554A2 (pt) 2013-09-24
EP2455105A3 (en) 2012-09-05
IL197363A0 (en) 2011-08-01
CO6150196A2 (es) 2010-04-20
EP2063918B1 (en) 2014-02-26
US8557776B2 (en) 2013-10-15
MA30780B1 (fr) 2009-10-01
PE20080850A1 (es) 2008-09-02
WO2008028688A3 (en) 2008-11-13
TW200829277A (en) 2008-07-16
US20080292548A1 (en) 2008-11-27
EP2455105B1 (en) 2016-02-17
JP5722966B2 (ja) 2015-05-27
CR10654A (es) 2009-04-14
EP3056509A1 (en) 2016-08-17
IL211527A0 (en) 2011-05-31
CA2858907A1 (en) 2008-03-13
MX2009002492A (es) 2009-08-28
EP2455105A2 (en) 2012-05-23
WO2008028688A2 (en) 2008-03-13
JP5603074B2 (ja) 2014-10-08
EP2279759A3 (en) 2013-04-17
EP2063918A2 (en) 2009-06-03
EP2289564A3 (en) 2012-11-14
IL211033A0 (en) 2011-04-28
EP2279759A2 (en) 2011-02-02
KR20090058553A (ko) 2009-06-09
AU2007294124A1 (en) 2008-03-13
AR062726A1 (es) 2008-11-26
RU2009112716A (ru) 2010-10-20
CL2007002620A1 (es) 2008-05-30
TN2009000063A1 (en) 2010-08-19
IL211526A0 (en) 2011-05-31
JP2014028813A (ja) 2014-02-13
EP2289564A2 (en) 2011-03-02
JP2010503618A (ja) 2010-02-04
CA2662449A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
NO20091428L (no) Forbindelser og metoder for 18F-merkede midler
NO20083598L (no) Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
CL2008002703A1 (es) Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios.
NO20071880L (no) Diagnostic Compounds
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
NO20085004L (no) Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
EA201000269A1 (ru) Новые гербициды
CO6450666A2 (es) Compuesto de piridazinona y su uso
EA201101148A1 (ru) Новые гербициды
EA201101099A1 (ru) Гербициды, полученные из циклопентадиона
EA201101060A1 (ru) Новые гербициды
MX385354B (es) Sales de xantilio 3,6-disustituidas.
UA106880C2 (uk) Нові гербіциди
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.
NO20090233L (no) Ny sammensetning som har affinitet for amyloid
NO20091735L (no) Radiofluorering
EA201101097A1 (ru) Новые микробиоциды
EA200901142A1 (ru) 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
NO20080468L (no) Diazepinokinoliner, synteser av disse samt intermediater
WO2009003672A3 (en) Novel microbiocides
NO20074897L (no) Radioaktive halogenmerkede fenyloksyanilinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application